New Perspectives on Antimicrobial Agents: Fosmanogepix. (PubMed, Antimicrob Agents Chemother) - Jun 5, 2026 - "Novel first-in-class antifungal agents have been recently approved (ibrexafungerp) or are currently being tested in clinical trials and are available via expanded access programs (olorofim, fosmanogepix). Novel gepix compounds have been developed and could make their niche in the future (e.g., APX2039, prodrug: APX2096, for cryptococcal meningitis, and APX2020, prodrug: APX2097, for coccidioidomycosis). This review discusses the future place of fosmanogepix in the antifungal armamentarium against IFIs."
Journal • Candidiasis • CNS Disorders • Infectious Disease • Pulmonary Disease • Respiratory Diseases
|